Navigation Links
MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software
Date:6/1/2010

HELSINKI, June 1, 2010 /PRNewswire/ -- MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world's largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease - to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.

"The latest research - such as The Cancer Genome Atlas funded by the NIH - demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes. The MediSapiens software gives personalized and clinically applicable insight into each patient's cancer," says Tommi Pisto, CEO and Co-founder of MediSapiens.

"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer. Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients," comments Professor Olli Kallioniemi, MediSapiens board member and director of the Institute for Molecular Medicine Finland (FIMM).

About MediSapiens

MediSapiens, the world's first software company for personalized cancer medicine in oncology clinics and new drug development, hosts world's largest unified gene expression database. With the data online, oncologists have access to evaluate individual patient's genetic signature for the optimized treatment strategy, and scientists understand how genes work across all human tissues. Company's bioinformatics science and peer-reviewed data is based on the research since 2005 by VTT Technical Research Centre of Finland and its collaborators. Visit http://www.medisapiens.fi for more information.

About Veraventure

Veraventure, with assets under management exceeding EUR 100m, is one of the largest early stage funds in Nordic countries. Veraventure makes direct investments in early-stage research, development and innovation intensive enterprises. It also acts as the hub for early-stage venture capital and angel investors as it manages national business angel network with over 100 registered angel investors. Visit http://www.veraventure.fi/company for more information.

About Eqvitec

Eqvitec Partners is one of the largest technology oriented private equity firms in Northern Europe. The company was founded in 1997 and employs 10 investment professionals in Helsinki and Stockholm. Eqvitec Partners currently advises three funds with a total capital base of over EUR 300 million. The funds invest in technology companies in the expansion stage. At the moment the funds have investments in 30 companies and have carried out over 40 exits. Visit http://www.eqvitec.com for more information.

About VTT Ventures

VTT Ventures Ltd is a development company that generates and develops spin-offs based on VTT's technology. We work closely with more than 2,500 VTT researchers and scientists to find the most valuable new technologies to commercialize. Through us, entrepreneurs have access to innovative ideas and know-how of more than 300 patent families. This is the bases for the dealflow that enables us to create growth companies with global potential. Visit http://www.vttventures.fi for more information.

About Lifeline Ventures

Lifeline Ventures, a venture accelerator and early-stage investment fund, co-creates growth companies in health and technology. Being entrepreneurs, we are active team members for an early-stage venture for 12-24 months. Visit http://www.lifelineventures.com for more information.

    Media contact:

    Timo Ahopelto
    VP Strategy
    MediSapiens
    Email: timo.ahopelto@medisapiens.fi
    Telephone: +358-400-569-628


'/>"/>
SOURCE MediSapiens Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
3. Karmanos Cancer Institutes Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool
4. Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits
5. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
6. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
7. Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million
8. Breathe Technologies Secures $23 Million in Series C Financing
9. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
10. Curexo Technology Corporation Raises $13.2 Million
11. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Visiomed, the French leader in medical ... changing the landscape of healthcare with their innovative ... custom-made solutions. Recognizing the rising demand of self-monitoring ... without walls, Visiomed has launched BewellConnect, the most ... professionals that is empowering the lives of patients. ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association ... Annual Meeting. KLS is a longtime supporter of the event. , "We are ... Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
(Date:2/23/2017)... ... (PRWEB) February 23, 2017 -- ... to come together to combine its favorite springtime pastime – ... fruit – apples! To celebrate National Nutrition Month, the U.S. ... Madness” bracket tournament – a five-week, five-round online competition spotlighting ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
Breaking Medicine News(10 mins):